Company profile for Muvon Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

MUVON Therapeutics is a clinical stage Life Science Spin-off from the University of Zurich developing an autologous cell therapy for the regeneration of skeletal muscle tissue aiming to provide safe and effective treatments to millions of patients suffering from seriously debilitating diseases by not only repairing damaged tissue but also increase the regenerative potential of weakened muscles. Our initial area of focus is the...
MUVON Therapeutics is a clinical stage Life Science Spin-off from the University of Zurich developing an autologous cell therapy for the regeneration of skeletal muscle tissue aiming to provide safe and effective treatments to millions of patients suffering from seriously debilitating diseases by not only repairing damaged tissue but also increase the regenerative potential of weakened muscles. Our initial area of focus is the treatment of stress urinary incontinence in women, supporting them respectfully throughout their journey to a healthy life.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Switzerland
Address
Address
Weinbergstrasse 35 WEH G-Stock 8092 Zürich
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

AMWC Asia-TDAC

AMWC Asia-TDAC

Not Confirmed

envelop Contact Supplier

AMWC Asia-TDAC

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/12/18/3207470/0/en/MUVON-Therapeutics-Appoints-Dr-Christine-G%C3%BCnther-as-Chief-Technology-Officer.html

GLOBENEWSWIRE
18 Dec 2025

https://www.globenewswire.com/news-release/2025/12/03/3198662/0/en/MUVON-Therapeutics-Reports-Positive-Phase-2-Results-for-its-First-in-Class-Muscle-Precursor-Cell-MPC-based-Tissue-Engineered-Therapy-Showing-Clinically-Meaningful-and-Statistically.html

GLOBENEWSWIRE
03 Dec 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty